JP2012504634A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504634A5 JP2012504634A5 JP2011530173A JP2011530173A JP2012504634A5 JP 2012504634 A5 JP2012504634 A5 JP 2012504634A5 JP 2011530173 A JP2011530173 A JP 2011530173A JP 2011530173 A JP2011530173 A JP 2011530173A JP 2012504634 A5 JP2012504634 A5 JP 2012504634A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- hvr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 44
- 108090001123 antibodies Proteins 0.000 claims 44
- 125000003275 alpha amino acid group Chemical group 0.000 claims 36
- 102000001756 Notch2 Receptor Human genes 0.000 claims 15
- 108010029751 Notch2 Receptor Proteins 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 6
- 229920000453 Consensus sequence Polymers 0.000 claims 4
- 230000035693 Fab Effects 0.000 claims 3
- 206010025650 Malignant melanoma Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 230000036210 malignancy Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 239000008177 pharmaceutical agent Substances 0.000 claims 3
- 108091006028 chimera Proteins 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
Claims (31)
- Notch2 NRRに結合し、Notch2活性を阻害するモノクローナル抗体であって、10nM以下のKdでNotch2 NRRに結合するモノクローナル抗体。
- Notch2以外のNotchファミリに有意に結合しない、請求項1に記載の抗体。
- マウスNotch2 NRRおよびヒトNotch2 NRRに結合する、請求項1に記載の抗体。
- (a) 配列番号:3のコンセンサス配列と一致するアミノ酸配列を含むHVR-H1;
(b) 配列番号:4のアミノ酸配列を含むHVR-H2;
(c) 配列番号:5のアミノ酸配列を含むHVR-H3;
(d) 配列番号:10のコンセンサス配列と一致するアミノ酸配列を含むHVR-L1;
(e) 配列番号:14のコンセンサス配列と一致するアミノ酸配列を含むHVR-L2;及び、
(f) 配列番号:19のコンセンサス配列と一致するアミノ酸配列を含むHVR-L3
を含む、請求項1に記載の抗体。 - 配列番号:1−2から選択されるアミノ酸配列を含むHVR-H1;配列番号:6−9から選択されるアミノ酸配列を含むHVR-L1;配列番号:11−13から選択されるアミノ酸配列を含むHVR-L2;及び、配列番号:15−18から選択されるアミノ酸配列を含むHVR-L3、を含んでなる、請求項4に記載の抗体。
- HVR-H1が配列番号:1のアミノ酸配列を含み、HVR-L1が配列番号:6のアミノ酸配列を含み、HVR-L2が配列番号:11のアミノ酸配列を含み、そして、HVR-L3が配列番号:15のアミノ酸配列を含む、請求項5に記載の抗体。
- HVR-H1が配列番号:2のアミノ酸配列を含み、HVR-L1が配列番号:7のアミノ酸配列を含み、HVR-L2が配列番号:11のアミノ酸配列を含み、そして、HVR-L3が配列番号:16のアミノ酸配列を含む、請求項5に記載の抗体。
- HVR-H1が配列番号:2のアミノ酸配列を含み、HVR-L1が配列番号:8のアミノ酸配列を含み、HVR-L2が配列番号:12のアミノ酸配列を含み、そして、HVR-L3が配列番号:17のアミノ酸配列を含む、請求項5に記載の抗体。
- HVR-H1が配列番号:2のアミノ酸配列を含み、HVR-L1が配列番号:9のアミノ酸配列を含み、HVR-L2が配列番号:13のアミノ酸配列を含み、そして、HVR-L3が配列番号:18のアミノ酸配列を含む、請求項5に記載の抗体。
- ヒトVHアクセプター2フレームワークおよびヒトVLκサブグループIコンセンサスフレームワークから選択される少なくとも一のフレームワークをさらに含む、請求項4に記載の抗体。
- 配列番号:20−21から選択されるアミノ酸配列に少なくとも90%の配列同一性を有する重鎖可変ドメインと、配列番号:22−25から選択されるアミノ酸配列に少なくとも90%の配列同一性を有する軽鎖可変ドメインとを含む、請求項1に記載の抗体。
- 配列番号:20のアミノ酸配列に少なくとも90%の配列同一性を有する重鎖可変ドメインと、配列番号:22のアミノ酸配列に少なくとも90%の配列同一性を有する軽鎖可変ドメインとを含む、請求項11に記載の抗体。
- 重鎖可変ドメインが配列番号:20のアミノ酸配列を含み、軽鎖可変ドメインが配列番号:22のアミノ酸配列を含む、請求項12に記載の抗体。
- 配列番号:21のアミノ酸配列に少なくとも90%の配列同一性を有する重鎖可変ドメインと、配列番号:23−25から選択されるアミノ酸配列に少なくとも90%の配列同一性を有する軽鎖可変ドメインとを含む、請求項11に記載の抗体。
- 重鎖可変ドメインが配列番号:21のアミノ酸配列を含み、軽鎖可変ドメインが配列番号:23−25から選択されるアミノ酸配列を含む、請求項14に記載の抗体。
- 抗体D、抗体D-1、抗体D-2又は抗体D-3から選択した抗体と同じエピトープに結合する、請求項1に記載の抗体。
- Notch2のLNR−AドメインおよびHD−Cドメインに結合する、請求項16に記載の抗体。
- Notch2 NRRに結合し、Notch2活性を阻害し、Notch2 NRRへの結合について抗体D、抗体D−1、抗体D−2および抗体D−3から選択される抗体と競合する、抗Notch2 NRR抗体。
- Fab、Fab'-SH、Fv、scFv又は(Fab')2の断片から選択される抗体断片である、請求項1から18の何れか一に記載の抗体。
- ヒト、ヒト化、又はキメラである、請求項1から19の何れか一に記載の抗体。
- 請求項1から18の何れか一の抗体にNotch2を発現する細胞を曝すことを含む、Notch2活性の阻害方法。
- Notch2の発現又は活性の増加と関連する疾患を治療するための医薬であって、請求項1から18の何れか一に記載の抗体の有効量を含有してなる医薬。
- B細胞悪性腫瘍を治療するための医薬であって、請求項1から18の何れか一に記載の抗体の有効量を含有してなる医薬。
- メラノーマを治療するための医薬であって、請求項1から18の何れか一に記載の抗体の有効量を含有してなる医薬。
- Notch2の発現又は活性の増加と関係する疾患を治療するための医薬を製造するための、請求項1から18の何れか一に記載の抗体の使用。
- B細胞悪性腫瘍を治療するための医薬を製造するための、請求項1から18の何れか一に記載の抗体の使用。
- メラノーマを治療するための医薬を製造するための、請求項1から18の何れか一に記載の抗体の使用。
- 医薬として使用するための請求項1から18の何れか一に記載の抗体。
- Notch2の発現又は活性の増加と関係する疾患の治療に使用するための、請求項1から18の何れか一に記載の抗体。
- B細胞悪性腫瘍の治療に使用するための、請求項1から18の何れか一に記載の抗体。
- メラノーマの治療に使用するための、請求項1から18の何れか一に記載の抗体。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10191708P | 2008-10-01 | 2008-10-01 | |
US61/101,917 | 2008-10-01 | ||
PCT/US2009/059028 WO2010039832A1 (en) | 2008-10-01 | 2009-09-30 | Anti-notch2 antibodies and methods of use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015042089A Division JP2015145379A (ja) | 2008-10-01 | 2015-03-04 | 抗notch2抗体および使用方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012504634A JP2012504634A (ja) | 2012-02-23 |
JP2012504634A5 true JP2012504634A5 (ja) | 2012-11-15 |
JP5710487B2 JP5710487B2 (ja) | 2015-04-30 |
Family
ID=41349057
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011530173A Active JP5710487B2 (ja) | 2008-10-01 | 2009-09-30 | 抗notch2抗体および使用方法 |
JP2015042089A Pending JP2015145379A (ja) | 2008-10-01 | 2015-03-04 | 抗notch2抗体および使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015042089A Pending JP2015145379A (ja) | 2008-10-01 | 2015-03-04 | 抗notch2抗体および使用方法 |
Country Status (18)
Country | Link |
---|---|
US (5) | US8404239B2 (ja) |
EP (1) | EP2334331B1 (ja) |
JP (2) | JP5710487B2 (ja) |
KR (1) | KR101712214B1 (ja) |
CN (1) | CN102170909B (ja) |
AR (1) | AR073717A1 (ja) |
AU (1) | AU2009298569A1 (ja) |
BR (1) | BRPI0913827A2 (ja) |
CA (1) | CA2736429A1 (ja) |
CL (1) | CL2011000711A1 (ja) |
ES (1) | ES2541726T3 (ja) |
IL (1) | IL211623A0 (ja) |
MX (1) | MX2011002928A (ja) |
PE (1) | PE20120080A1 (ja) |
RU (1) | RU2580029C2 (ja) |
TW (1) | TW201018484A (ja) |
WO (1) | WO2010039832A1 (ja) |
ZA (1) | ZA201101651B (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7919092B2 (en) | 2006-06-13 | 2011-04-05 | Oncomed Pharmaceuticals, Inc. | Antibodies to notch receptors |
EP2125887A4 (en) | 2007-01-24 | 2010-11-10 | Oncomed Pharm Inc | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER |
PL2307459T3 (pl) | 2008-07-08 | 2015-05-29 | Oncomed Pharm Inc | Czynniki wiążące receptor Notch1 i sposoby ich stosowania |
US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
BRPI0913827A2 (pt) * | 2008-10-01 | 2020-12-29 | Genentech, Inc | Anticorpo monoclonal, método para inibir a atividade de notch2, método para tratar uma doença, método para tratar uma malignidade, método para tratar um melanoma, usos de um anticorpo e anticorpo nrr anti-notch2 |
WO2012047583A2 (en) * | 2010-09-27 | 2012-04-12 | Janssen Biotech, Inc. | Antibodies binding human collagen ii |
US8906649B2 (en) | 2010-09-27 | 2014-12-09 | Janssen Biotech, Inc. | Antibodies binding human collagen II |
BR112014008212A2 (pt) | 2011-10-05 | 2017-06-13 | Genentech Inc | método para tratar uma condição hepática, método de indução por diferenciação hepática e método de redução de proliferação anormal do ducto biliar |
WO2013173542A1 (en) * | 2012-05-16 | 2013-11-21 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with notch2/3 antibodies |
RU2018130986A (ru) | 2012-08-13 | 2018-10-09 | Дженентек, Инк. | Антитела к jagged и способы их применения |
EP2970468B1 (en) | 2013-03-13 | 2021-07-07 | Novartis AG | Notch2 binding molecules for treating respiratory diseases |
WO2014151866A1 (en) * | 2013-03-15 | 2014-09-25 | Genentech, Inc. | Compositions and methods for diagnosis and treatment of hepatic cancers |
JP6571115B2 (ja) | 2014-02-12 | 2019-09-04 | ジェネンテック, インコーポレイテッド | 抗jagged1抗体及び使用方法 |
KR20170029490A (ko) | 2014-07-11 | 2017-03-15 | 제넨테크, 인크. | 노치 경로 억제 |
TWI713590B (zh) * | 2015-09-26 | 2020-12-21 | 財團法人國家衛生研究院 | Notch 訊息傳遞路徑之活化劑用於治療掉髮之用途及其組成物 |
GB201521447D0 (en) * | 2015-12-04 | 2016-01-20 | Ucb Biopharma Sprl | De novo antibody design |
WO2018222880A1 (en) * | 2017-05-31 | 2018-12-06 | Trustees Of Boston University | Mechano-activated control of gene expression |
MX2023000617A (es) * | 2020-07-17 | 2023-02-13 | Genentech Inc | Anticuerpos anti-notch2 y metodos de uso. |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
IE20030749A1 (en) | 1991-05-03 | 2003-11-12 | Indiana University Foundation | Human notch and delta binding domains in torporythmic proteins, and methods based thereon |
US5786158A (en) | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
US20050112121A1 (en) | 1992-04-30 | 2005-05-26 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
RO118524B1 (ro) | 1992-11-13 | 2003-06-30 | Idec Pharmaceuticals Corp San | Metoda pentru tratarea unei tulburari legata de celulele b |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5780300A (en) | 1995-09-29 | 1998-07-14 | Yale University | Manipulation of non-terminally differentiated cells using the notch pathway |
US20050158859A1 (en) | 1995-09-29 | 2005-07-21 | Yale University | Manipulation of non-terminally differentiated cells using the Notch pathway |
US6692919B1 (en) | 1997-07-23 | 2004-02-17 | Yale University | Activated forms of notch and methods based thereon |
US6436650B1 (en) | 1997-07-23 | 2002-08-20 | Yale University | Activated forms of notch and methods based thereon |
AU768269B2 (en) | 1998-10-02 | 2003-12-04 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Apoptosis inducing agents and methods |
US8084258B2 (en) | 1999-07-12 | 2011-12-27 | University Of Basel | Manipulation of tissue of organ type using the notch pathway |
DK1318830T3 (da) | 2000-09-22 | 2013-01-28 | Genentech Inc | Konstitutivt aktiv form af Notch1-receptor eller et anti-Notch1-receptor til behandling af prostatacancer |
EP2295575A3 (en) | 2000-12-04 | 2011-07-06 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US7755007B2 (en) | 2003-04-17 | 2010-07-13 | K&H Manufacturing, Inc | Heated pet mat |
US20050232927A1 (en) | 2004-02-03 | 2005-10-20 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
US20070077245A1 (en) | 2004-08-04 | 2007-04-05 | The Brigham And Women's Hospital, Inc. | NOTCH mutations leading to increased receptor signaling |
WO2006053063A2 (en) | 2004-11-05 | 2006-05-18 | The Regents Of The University Of California | Notch-1 assay to detect neurodegenerative diseases |
WO2006068822A1 (en) | 2004-12-20 | 2006-06-29 | Genentech, Inc. | Notch receptor agonists and uses |
EP1962895B2 (en) | 2005-12-16 | 2016-01-20 | Regeneron Pharmaceuticals, Inc. | THERAPEUTIC USE OF A Dll4 ANTAGONIST AND A VEGF INHIBITOR FOR INHIBITING TUMOR GROWTH |
US20080241150A1 (en) * | 2006-05-15 | 2008-10-02 | The Brigham And Women's Hospital, Inc. | Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1 |
US7919092B2 (en) * | 2006-06-13 | 2011-04-05 | Oncomed Pharmaceuticals, Inc. | Antibodies to notch receptors |
PE20081264A1 (es) | 2006-10-19 | 2008-10-01 | Genentech Inc | Anticuerpos agonistas anti-notch3 |
US7935791B2 (en) | 2006-12-18 | 2011-05-03 | Genentech, Inc. | Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases |
EP2125887A4 (en) | 2007-01-24 | 2010-11-10 | Oncomed Pharm Inc | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER |
PE20090321A1 (es) | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
PL2307459T3 (pl) | 2008-07-08 | 2015-05-29 | Oncomed Pharm Inc | Czynniki wiążące receptor Notch1 i sposoby ich stosowania |
BRPI0913827A2 (pt) * | 2008-10-01 | 2020-12-29 | Genentech, Inc | Anticorpo monoclonal, método para inibir a atividade de notch2, método para tratar uma doença, método para tratar uma malignidade, método para tratar um melanoma, usos de um anticorpo e anticorpo nrr anti-notch2 |
RU2011151287A (ru) * | 2009-06-18 | 2013-07-27 | Пфайзер Инк. | АНТИ Notch-1 АНТИТЕЛА |
-
2009
- 2009-09-30 BR BRPI0913827-7A patent/BRPI0913827A2/pt not_active IP Right Cessation
- 2009-09-30 ES ES09793181.0T patent/ES2541726T3/es active Active
- 2009-09-30 TW TW98133312A patent/TW201018484A/zh unknown
- 2009-09-30 JP JP2011530173A patent/JP5710487B2/ja active Active
- 2009-09-30 WO PCT/US2009/059028 patent/WO2010039832A1/en active Application Filing
- 2009-09-30 US US12/570,267 patent/US8404239B2/en active Active
- 2009-09-30 AR ARP090103776 patent/AR073717A1/es unknown
- 2009-09-30 CN CN200980139202.1A patent/CN102170909B/zh active Active
- 2009-09-30 CA CA 2736429 patent/CA2736429A1/en not_active Abandoned
- 2009-09-30 RU RU2011117237/10A patent/RU2580029C2/ru not_active IP Right Cessation
- 2009-09-30 PE PE2011000807A patent/PE20120080A1/es not_active Application Discontinuation
- 2009-09-30 EP EP20090793181 patent/EP2334331B1/en active Active
- 2009-09-30 KR KR1020117007489A patent/KR101712214B1/ko active IP Right Grant
- 2009-09-30 MX MX2011002928A patent/MX2011002928A/es active IP Right Grant
- 2009-09-30 AU AU2009298569A patent/AU2009298569A1/en not_active Abandoned
-
2011
- 2011-03-03 ZA ZA2011/01651A patent/ZA201101651B/en unknown
- 2011-03-08 IL IL211623A patent/IL211623A0/en unknown
- 2011-03-31 CL CL2011000711A patent/CL2011000711A1/es unknown
-
2013
- 2013-02-22 US US13/773,843 patent/US20140037643A1/en not_active Abandoned
- 2013-10-11 US US14/051,699 patent/US20140314782A1/en not_active Abandoned
-
2014
- 2014-06-06 US US14/298,488 patent/US20170204175A9/en not_active Abandoned
-
2015
- 2015-03-04 JP JP2015042089A patent/JP2015145379A/ja active Pending
-
2017
- 2017-07-21 US US15/656,967 patent/US20180057589A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012504634A5 (ja) | ||
RU2011117237A (ru) | АНТИТЕЛА ПРОТИВ Notch2 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
JP2016507470A5 (ja) | ||
JP2018035138A5 (ja) | ||
JP2020500538A5 (ja) | ||
JP2013538553A5 (ja) | ||
JP2012513214A5 (ja) | ||
JP2017528476A5 (ja) | ||
JP2019523295A5 (ja) | ||
JP2018500014A5 (ja) | ||
JP2017534577A5 (ja) | ||
JP2011518125A5 (ja) | ||
JP2016503413A5 (ja) | ||
JP2017514461A5 (ja) | ||
JP2012504955A5 (ja) | ||
JP2018108086A5 (ja) | ||
RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
JP2014511179A5 (ja) | ||
JP2015522252A5 (ja) | ||
JP2017507652A5 (ja) | ||
JP2016533335A5 (ja) | ||
JP2014158469A5 (ja) | ||
JP2015501149A5 (ja) | ||
JP2010516229A5 (ja) | ||
JP2006522830A5 (ja) |